Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Cwm LLC

Cwm LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 14.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,391 shares of the biopharmaceutical company’s stock after purchasing an additional 1,980 shares during the period. Cwm LLC’s holdings in Catalyst Pharmaceuticals were worth $334,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 579 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Catalyst Pharmaceuticals by 57.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 2,002 shares during the last quarter. US Bancorp DE boosted its stake in Catalyst Pharmaceuticals by 17.8% during the 1st quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 1,105 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new position in Catalyst Pharmaceuticals during the 1st quarter valued at $182,000. Finally, Headlands Technologies LLC bought a new position in Catalyst Pharmaceuticals during the 1st quarter valued at $188,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Weiss Ratings restated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday. Finally, Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $33.20.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $20.96 on Friday. The firm’s 50 day moving average is $20.33 and its 200-day moving average is $21.87. The stock has a market capitalization of $2.57 billion, a P/E ratio of 12.70, a P/E/G ratio of 0.84 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $53.11 million for the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a return on equity of 40.78%. As a group, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current fiscal year.

Catalyst Pharmaceuticals declared that its board has authorized a stock repurchase program on Wednesday, October 1st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 8.3% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 30,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.30, for a total value of $609,000.00. Following the transaction, the insider directly owned 271,039 shares of the company’s stock, valued at $5,502,091.70. This trade represents a 9.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David S. Tierney sold 26,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $20.20, for a total transaction of $525,200.00. Following the completion of the transaction, the director directly owned 379,620 shares in the company, valued at approximately $7,668,324. This trade represents a 6.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 243,970 shares of company stock worth $4,927,241. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.